← All candidates
Two insiders bought $49.4K in a single day.
24 filings on record.
ANIXAnixa Biosciences Inc
NasdaqCM · Healthcare · $93.17M
$2.69
-3.93% · Sep 15
Two insiders bought $49.4K in a single day.
Led by Titterton Lewis H jr, director.
Price · 1Y · daily● 10 buys◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what ANIX ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$93.17M
Float
32.2M
92% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Executive Officer
Kumar Amit
Bought $52.5K on Jun 12 — 21,000 sh @ $2.50, held direct, 3.3% of their stake.
1 of 1 position beat the S&P
Director
Titterton Lewis H jr
Bought $31.4K on Jul 11 — 10,000 sh @ $3.14, held direct, 1.1% of their stake.
0 of 2 positions beat the S&P
Director
Baskies Arnold M
Bought $30.4K on Jan 28 — 10,000 sh @ $3.04, held direct, 7.4% of their stake.
1 of 2 positions beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
16 more transactions on Pro →Context
Wall St
$11.00 avg target
+308.9% vs today · 3 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
3 of 4 quarters beat
Q2 '26−$0.07 act+$0.03
Q1 '26−$0.08 act+$0.01
Q4 '25−$0.09 act+$0.00
Q3 '25−$0.07 act+$0.03
Coverage
Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should KnowZacks · 07-22Anixa Biosciences secures Korean patent for breast cancer vaccinePharmaceutical Technology · 06-30Here's Why You Should Add ANIX Stock to Your Portfolio NowZacks · 06-25Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference
The file stays open
24 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice